Alpha 2.0
Login Register
» Authors » Shanchun Zhang

Shanchun Zhang

Explore the profile of Shanchun Zhang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 858
Followers 0
Related Specialties
Chemistry
Endocrinology
Nutritional Sciences
Top 10 Co-Authors
Xiping Xu
Xiaobin Wang
Yunxian Yu
Qingsong Liu
Cheng Chen
Jing Liu
Li Wang
Xiumei Hong
Aoli Wang
Beilei Wang
Published In
J Med Chem
Oncotarget
Eur J Med Chem
Hum Genet
J Clin Endocrinol Metab
Affiliations
Soon will be listed here.
Recent Articles
1.
Pre-Shaped Burst-Mode Hybrid MOPA Laser System at 10 kHz Pulse Frequency
Zhang S, Yu X, Peng J, Cao Z
Sensors (Basel) . 2023 Jan; 23(2). PMID: 36679630
A temporal pre-shaped burst-mode hybrid fiber-bulk laser system was illustrated at a 10 kHz rate with a narrow spectral linewidth. A theoretical model was proposed to counteract the temporal profile...
2.
Local infiltration of HYR-PB21, a sustained-release formulation of bupivacaine, provides analgesia and reduces opioid requirement after haemorrhoidectomy: a randomised controlled trial
Cui J, Xu Q, Yu Z, Sun J, Zheng Y, Huang W, et al.
Br J Anaesth . 2022 Oct; 129(6):970-976. PMID: 36243580
Background: HYR-PB21 is a new sustained-release formulation of bupivacaine indicated for controlling postoperative pain. The objectives of this study were to investigate the analgesic efficacy and safety profile of HYR-PB21...
3.
HYR-PB21-LA, a potential extended-release bupivacaine formulation, produces long-lasting local anesthesia in rats and guinea pigs
Peng J, Liu C, Liu J, Wang Y, Lu X, Sun H, et al.
Reg Anesth Pain Med . 2020 Mar; 45(5):367-372. PMID: 32170037
Background: Effective postoperative pain management plays a key role in enhancing recovery of patients after surgery. Bupivacaine hydrochloride is one of the most commonly local anesthetics used for the postoperative...
4.
Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor
Liang X, Li F, Chen C, Jiang Z, Wang A, Liu X, et al.
Eur J Med Chem . 2018 Jul; 156:831-846. PMID: 30053721
PI3Kδ, which is mainly expressed in leukocytes, plays a critical role in B-cell receptor mediated signaling pathway and has been extensively studied as a drug discovery target for B cell...
5.
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic...
Wang Q, Liu F, Qi S, Qi Z, Yan X, Wang B, et al.
Eur J Med Chem . 2018 Mar; 150:366-384. PMID: 29544149
Through exploration of the non-highly conserved allosteric hydrophobic pocket generated by DFG-out shifting in the inactive conformation, we discovered a highly selective type II PDGFRα kinase inhibitor 15i (CHMFL-PDGFRα-159), which...
6.
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase...
Wang A, Li X, Chen C, Wu H, Qi Z, Hu C, et al.
J Med Chem . 2017 Sep; 60(20):8407-8424. PMID: 28956923
FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study that ibrutinib (9) exhibited...
7.
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of...
Chen Y, Wu J, Wang A, Qi Z, Jiang T, Chen C, et al.
Eur J Med Chem . 2017 Aug; 139:674-697. PMID: 28850922
Recently, more and more concomitant EGFR mutations and ALK rearrangement are observed from the clinic, which still lacks effective single-agent therapy. Starting from ALK inhibitor 14 (TAE684), we have developed...
8.
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
Hu C, Wang A, Wu H, Qi Z, Li X, Yan X, et al.
Oncotarget . 2017 Apr; 8(11):18359-18372. PMID: 28407693
EGFR T790M mutation accounts for about 40-55% drug resistance for the first generation EGFR kinase inhibitors in the NSCLC. Starting from ibrutinib, a highly potent irreversible BTK kinase inhibitor, which...
9.
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor
Liang Q, Chen Y, Yu K, Chen C, Zhang S, Wang A, et al.
Eur J Med Chem . 2017 Mar; 131:107-125. PMID: 28315597
Currently there are several irreversible BTK inhibitors targeting Cys481 residue under preclinical or clinical development. However, most of these inhibitors also targeted other kinases such as BMX, JAK3, and EGFR...
10.
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode
Wang A, Li X, Wu H, Zou F, Yan X, Chen C, et al.
J Med Chem . 2017 Mar; 60(7):2944-2962. PMID: 28282122
On the basis of Ibrutinib's core pharmacophore, which was moderately active to EGFR T790M mutant, we discovered novel epidermal growth factor receptor (EGFR) inhibitor compound 19 (CHMFL-EGFR-202), which potently inhibited...